Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Low-dose metronomic chemotherapy involves the frequent administration of comparatively low doses of cytotoxic agents with no extended breaks, and it may be as efficient as and less toxic than the conventional maximum tolerated dose therapy. This study evaluated the feasibility and therapeutic efficacy of metronomic chemotherapy in patients with advanced hepatocellular carcinoma (HCC) with major portal vein thrombosis (PVT). Methods: Thirty consecutive HCC patients with major PVT with or without extrahepatic metastasis were prospectively allocated to metronomic chemotherapy consisting of epirubicin being infused through the correct hepatic artery at a dose of 30 mg/body surface area (BSA) every 4 weeks, and cisplatin (15 mg/BSA) and 5-fluorouracil (50 mg/BSA) every week for 3 weeks, with intervening 1 week breaks. The treatment response was assessed using response evaluation criteria in solid tumors (RECIST). Results: In total, 116 cycles of metronomic chemotherapy were administered to the 30 patients,with a median of 3 cycles given to individual patients (range, 1-15 cycles). Six patients (20.0%) achieved a partial response and six patients (20.0%) had stable disease. The median time to disease progression and overall survival were 63 days (range, 26-631 days) and 162 days (95% confidence interval; range, 62-262 days), respectively. Overall survival was significantly associated with baseline alpha-fetoprotein level (P=0.001) and tumor response (P=0.005). The baseline alpha-fetoprotein level was significantly associated with the disease control rate (P=0.007). Adverse events were tolerable and managed successfully with conservative treatment. Conclusions: Metronomic chemotherapy may be a safe and useful palliative treatment in HCC patients with major PVT. (Korean J Hepatol 2012;18:32-40)
Abstract
Background/Aims: Low-dose metronomic chemotherapy involves the frequent administration of comparatively low doses of cytotoxic agents with no extended breaks, and it may be as efficient as and less toxic than the conventional maximum tolerated dose therapy. This study evaluated the feasibility and therapeutic efficacy of metronomic chemotherapy in patients with advanced hepatocellular carcinoma (HCC) with major portal vein thrombosis (PVT). Methods: Thirty consecutive HCC patients with major PVT with or without extrahepatic metastasis were prospectively allocated to metronomic chemotherapy consisting of epirubicin being infused through the correct hepatic artery at a dose of 30 mg/body surface area (BSA) every 4 weeks, and cisplatin (15 mg/BSA) and 5-fluorouracil (50 mg/BSA) every week for 3 weeks, with intervening 1 week breaks. The treatment response was assessed using response evaluation criteria in solid tumors (RECIST). Results: In total, 116 cycles of metronomic chemotherapy were administered to the 30 patients,with a median of 3 cycles given to individual patients (range, 1-15 cycles). Six patients (20.0%) achieved a partial response and six patients (20.0%) had stable disease. The median time to disease progression and overall survival were 63 days (range, 26-631 days) and 162 days (95% confidence interval; range, 62-262 days), respectively. Overall survival was significantly associated with baseline alpha-fetoprotein level (P=0.001) and tumor response (P=0.005). The baseline alpha-fetoprotein level was significantly associated with the disease control rate (P=0.007). Adverse events were tolerable and managed successfully with conservative treatment. Conclusions: Metronomic chemotherapy may be a safe and useful palliative treatment in HCC patients with major PVT. (Korean J Hepatol 2012;18:32-40)
참고문헌 (22)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Bocci G, "Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy", Proc Natl Acad Sci U S A, 100, pp.12917~12922 (2003)
- Hanahan D, "Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice", J Clin Invest, 105, pp.1045~1047 (2000)
- Boucher E, "Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen)", Cancer Chemother Pharmacol, 50, pp.305~308 (2002)
- Kerbel RS, "The anti-angiogenic basis of metronomic chemotherapy", Nat Rev Cancer, 4, pp.423~436 (2004)
- Bertolini F, "Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells", Cancer Res, 63, pp.4342~4346 (2003)
- Man S, "Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water", Cancer Res, 62, pp.2731~2735 (2002)
- Stölting S, "Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis", Int J Clin Pharmacol Ther, 42, pp.652~653 (2004)
- Park ST, "Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis", CANCER CHEMOTHERAPY AND PHARMACOLOGY, 65, pp.1029~1037 (2010), springer
- Woo HY, "A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma", CANCER CHEMOTHERAPY AND PHARMACOLOGY, 65(2), pp.373~382 (2010)
- Llovet JM, "Design and endpoints of clinical trials in hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.698~711 (2008)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Browder T, "Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer", Cancer Res, 60, pp.1878~1886 (2000)
- Klement G, "Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity", J Clin Invest, 105, pp.R15~R24 (2000)
- Tulpule A, "Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma", Cancer, 95, pp.147~154 (2002)
- Colleoni M, "Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels", Ann Oncol, 13, pp.73~80 (2002)
- Spieth K, "Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study", Cancer Chemother Pharmacol, 52, pp.377~382 (2003)
- Ando E, "Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases", Cancer, 95, pp.588~595 (2002)
- Park JY, "Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma", CANCER, 110(1), pp.129~137 (2007)
- Oh HJ, "A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management", Cancer Chemotherapy and Pharmacology, 59(1), pp.9~15 (2007), Springer Verlag
- Jang JW, "Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma", CANCER CHEMOTHERAPY AND PHARMACOLOGY, 54, pp.415~420 (2004), SPRINGER
- Patt YZ, "Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b", Cancer, 72, pp.2574~2582 (1993)